New hope for advanced cancer: experimental drug SNV4818 enters human trials
Disease control
Recruiting now
This study is testing a new medicine called SNV4818 for people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 320 participants will receive…
Phase: PHASE1, PHASE2 • Sponsor: Pikavation Therapeutics, Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC